Without more proof of its effectiveness, Excellus is still considering the drug “investigational,” according to syracuse.com.
“Our health plan wants our members to have access to therapies that are safe, effective, and evidence-based as demonstrated by peer-reviewed clinical trials,” said Excellus Vice President Elizabeth Martin.
Aduhelm’s approval by the FDA is being reviewed by the HHS Office of Inspector General as of Aug. 4.
At the Becker's 5th Annual Fall Payer Issues Roundtable, taking place November 2–3 in Chicago, payer executives and healthcare leaders will come together to discuss value-based care, regulatory changes, cost management strategies and innovations shaping the future of payer-provider collaboration. Apply for complimentary registration now.
